Sarepta Therapeutics Inc New/ US8036071004 /
| 2024-04-25 10:00:00 PM | Chg. +3.1400 | Volume | Bid1:52:38 AM | Ask1:52:38 AM | High | Low |
|---|---|---|---|---|---|---|
| 127.3900USD | +2.53% | 1.69 mill. Turnover: 133.57 mill. |
125.5000Bid Size: 100 | 129.5000Ask Size: 1,200 | 130.6100 | 121.8000 |
GlobeNewswire
2022-03-08
Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program
GlobeNewswire
2022-03-01
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corpor...
GlobeNewswire
2022-03-01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2022-02-22
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corp...
GlobeNewswire
2022-02-01
Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to ...
GlobeNewswire
2022-02-01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2022-01-10
Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements ...
GlobeNewswire
2022-01-06
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2022-01-01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2021-12-01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2021-11-17
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development
GlobeNewswire
2021-11-17
Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors
GlobeNewswire
2021-11-03
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Development...
GlobeNewswire
2021-10-30
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2021-10-27
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developme...
GlobeNewswire
2021-10-14
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
GlobeNewswire
2021-10-12
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September ...
GlobeNewswire
2021-10-12
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
GlobeNewswire
2021-10-11
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patien...
GlobeNewswire
2021-10-04
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
GlobeNewswire
2021-10-04
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Ther...
GlobeNewswire
2021-10-01
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
